BeiGene’s 2025 Responsible Business & Sustainability Report highlights a 40.00 % year-over-year jump in product revenue to $5.30 billion, driven by expanding global uptake of its oncology portfolio. The company’s medicines are now approved in more than 75 markets, with cumulative treated patients reaching 2.00 million.

Pipeline depth continued to increase; 27 clinical candidates—20 of them internally discovered—are in development, and five new molecular entities advanced into the clinic during 2025. More than 27,000 patients have participated in over 175 trials worldwide.

Manufacturing scale-up supported the growth, yet BeiGene achieved its 2026 climate goal one year early: Scope 1 and 2 greenhouse-gas emissions per unit of internally manufactured commercial product fell by 25 % versus the 2021 baseline. A new target aims for a 50 % reduction by 2030 (2024 baseline). The company also set its first Scope 3 goal—a 10 % intensity cut by 2030.

Total headcount surpassed 12,000 across six continents. Engagement scores rose three points to 87 %, while voluntary turnover held at 8.00 %. Safety performance remained solid with zero lost-time incidents at R&D and manufacturing sites.

Capital deployment into communities continued through the BeOne Care Foundation, which funded six “Access to Cancer Care” programs and delivered 74,280 defined daily doses of therapy via its partnership with The Max Foundation.

Governance enhancements included a refreshed ESG oversight structure, a quantitative climate-risk assessment aligned with TCFD, and a strengthened global promotional-review process that approved more than 160 patient and HCP materials.

Looking ahead, BeiGene targets annual first-in-human entries for multiple new molecules, maintenance of engagement above 80 %, and further reductions in energy-related emissions intensity while sustaining rapid commercial growth.